Cynapsus Therapeutics Inc.: Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten …

Criteria for selection of the Top 10 Neurology Projects to Watch are:

Large market, large unmet need, with increasing opportunity

History of the molecule and drug

Strong science

Strong company

Diversity of indications

Potential for new opportunities beyond the initial indications

Multi-level partnering opportunities, i.e., biotech to biotech as well as pharma to biotech

Over one million people in the U.S. and an estimated 4 to 6 million people globally suffer from Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. OFF episodes are a complication of Parkinson's disease that leave patients rigid and unable to move and communicate. Approximately 25% to 50% of Parkinson's patients experience OFF episodes, which can occur 1 to 6 times daily and last between 30 and 120 minutes.

Today, apomorphine is the only drug that can rapidly convert a patient from OFF (unable to move) to ON (fully functional). Unfortunately for Parkinson's patients, apomorphine is primarily only available as a needle injection, which can be painful and difficult to administer.

Read the original:
Cynapsus Therapeutics Inc.: Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten ...